Tech Company Financing Transactions
Tmunity Therapeutics Funding Round
Be The Match BioTherapies, Gilead Sciences and Parker Institute for Cancer Immunotherapy invested in a funding round for Tmunity Therapeutics. This venture round closed on 1/24/2018.
Transaction Overview
Company Name
Announced On
1/24/2018
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3020 Market St. 535
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Website
Email Address
Not Recorded
Overview
Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy to patients with devastating diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Usman Azam
Chief Financial Officer
Graeme Bell
Chief Scientific Officer
Christina Coughlin
Chief Technical Officer
Jason Krentz
VP - Bus. Development
Michael Christiano
VP - General Counsel
Moji James
Browse more venture capital transactions:
Prev: 1/24/2018: Eta Compute venture capital transaction
Next: 1/24/2018: SheerID venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs